HALO - HALOZYME THERAPEUTICS, INC.

67.37
0.010   0.015%

Share volume: 1,262,332
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$67.36
0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
48%
Profitability 51%
Dept financing 24%
Liquidity 72%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.55%
1 Month
-16.29%
3 Months
7.14%
6 Months
-11.18%
1 Year
10.48%
2 Year
61.52%
Key data
Stock price
$67.37
P/E Ratio 
24.97
DAY RANGE
$66.26 - $68.00
EPS 
$2.64
52 WEEK RANGE
$47.50 - $82.22
52 WEEK CHANGE
$9.65
MARKET CAP 
7.914 B
YIELD 
N/A
SHARES OUTSTANDING 
118.017 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,655,688
AVERAGE 30 VOLUME 
$2,043,864
Company detail
CEO: Helen I. Torley
Region: US
Website: halozyme.com
Employees: 390
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

Recent news